BACKGROUND
Cardiovascular death (CVD) remains a leading cause of global mortality. Although semaglutide reduces major adverse cardiovascular events (MACE), the consistency and exact magnitude of its standalone effect on CVD across various patient phenotypes require comprehensive evaluation. This meta-analysis systemati...
G. Marino, S. Aquilani, S. D. Di Fusco et al.· Critical Pathways in Cardiol...· 0 citations
Background: Optimal blood pressure (BP) control remains elusive for millions of patients worldwide, often leading to resistant or secondary hypertension. Overactivation of the mineralocorticoid receptor (MR) drives this systemic pathology. While steroidal mineralocorticoid receptor antagonists (MRAs) are effective, the...
G. Marino, S. D. Di Fusco, E. Graziano et al.· Journal of Clinical Medicine· 0 citations
BACKGROUND
Nonstatin low-density lipoprotein (LDL)-cholesterol-lowering therapies are increasingly used in secondary prevention, familial hypercholesterolemia, and statin-intolerant patients, but adverse-event reporting is heterogeneous, and harmonized safety evidence remains limited.
OBJECTIVE
To evaluate the tolera...
A. Matteucci, M. Bonanni, S. D. Di Fusco et al.· Journal of Clinical Lipidolo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.